We demonstrated that SOX9 enhanced resistance of the BCL2‐overexpressing DLBCL subset against standard chemotherapy as well as a BCL2 inhibitor, indicating that DLBCL cells expressing high SOX9 levels rely on BCL2 to survive and further clarifying its oncogenic role in lymphomagenesis. Here, SOX9 is linked to diffuse large B-cell lymphoma.